Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zapping the brain to heal the liver: new trial tests TMS for fatty liver

NCT ID NCT07399600

Disease control Sponsor: The Affiliated Hospital of Hangzhou Normal University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a non-invasive brain stimulation technique called rTMS can reduce liver fat in people with alcohol-related fatty liver disease (MetALD). 105 participants will receive either personalized rTMS, standard rTMS, or a sham (placebo) treatment over 20 sessions. The goal is to see if targeting a deep brain reward center can improve liver health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
repetitive transcranial magnetic stimulation (rTMS)
What this could lead to
If it works, this could offer a non-invasive, drug-free way to reduce liver fat and improve metabolic health in people with alcohol-related fatty liver disease.
What could go wrong
This is an early-stage trial with only 105 participants, so results may not apply to everyone. The treatment is experimental, and its long-term benefits or risks are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 105 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants are able to understand the study protocol, requirements, and restrictions, are fully informed of potential adverse events, are willing to comply with follow-up visits, and voluntarily sign the informed consent form before enrollment. * Meet the diagnostic criteria for MASLD according to the Guidelines for the Prevention and Treatment of Metabolic (Non-Alcoholic) Fatty Liver Disease (2024 Edition), and fulfill the European definition of MetALD with moderate alcohol consumption (20-50 g/day for women; 30-60 g/day for men). * Age between 18 and 65 years. * Body mass index (BMI) \> 24 kg/m². * No history of alcohol abuse. Exclusion Criteria: * Contraindications to magnetic resonance imaging (MRI) or transcranial magnetic stimulation (TMS). * Mild cognitive impairment, defined as Montreal Cognitive Assessment (MoCA) score \< 25. * Severe comorbid somatic diseases or neurological disorders. * History of psychiatric disorders, or current use of antipsychotic medications. * Pregnant or breastfeeding women, or those planning pregnancy. * Previous TMS treatment within the last 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fatty liver are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome alcoholic liver disease fatty liver disease metabolic dysfunction and alcohol associated liver disease metabolic syndrome X

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fatty liver Liver diseases, alcoholic Metabolic syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Affiliated Hospital of Hangzhou Normal University

    Hangzhou, Zhejiang, 310015, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.